PDX1 and pancreatic adenocarcinoma: In this study, we report that gemcitabine and DMAPT/gemcitabine significantly increase median survival and decrease the incidence and multiplicity of pancreatic adenocarcinomas in LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice.